Cabozantinib (XL184, BMS-907351)

Cabozantinib (XL184, BMS-907351) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM in cell-free assays, respectively.

Price Stock Quantity  
USD 220 In stock
USD 110 In stock
USD 170 In stock
USD 470 In stock
USD 997 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Cabozantinib (XL184, BMS-907351) Chemical Structure

Cabozantinib (XL184, BMS-907351) Chemical Structure
Molecular Weight: 501.51

Validation & Quality Control

Customer Product Validation(4)

Quality Control & MSDS

Related Compound Libraries

Cabozantinib (XL184, BMS-907351) is available in the following compound libraries:

VEGFR Inhibitors with Unique Features

  • Pan VEGFR Inhibitors

    Regorafenib (BAY 73-4506) Pan-VEGFR inhibitor, VEGFR1/VEGFR2/VEGFR3, IC50=13 nM/4.2 nM/46 nM.

  • Most Potent VEGFR Inhibitor

    Axitinib VEGFR1, VEGFR2, VEGFR3, IC50=0.1 nM, 0.2 nM, 0.1-0.3 nM.

  • FDA-approved VEGFR Inhibitor

    Axitinib Approved by FDA for Renal Cell Carcinoma.

  • Classic VEGFR Inhibitor

    Dovitinib (TKI-258, CHIR-258) Multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit) with IC50 of 1 nM/2 nM, also potent to class IV (FGFR1/3) and class V (VEGFR1-4) RTKs with IC50 of 8-13 nM.

Product Information

  • Compare VEGFR Inhibitors
    Compare VEGFR Products
  • Research Area
  • Inhibition Profile

Product Description

Biological Activity

Description Cabozantinib (XL184, BMS-907351) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM in cell-free assays, respectively.
Targets VEGFR2/KDR [1]
(Cell-free assay)
c-Met [1]
(Cell-free assay)
Kit [1]
(Cell-free assay)
(Cell-free assay)

 View  More

IC50 0.035 nM 1.3 nM 4.6 nM 6.0 nM
In vitro XL184 has weak inhibitory activity against RON and PDGFRβ with IC50 of 124 nM and 234 nM, respectivey, and has low activity against FGFR1 with IC50 of 5.294 μM. [1] XL184 at low concentration (0.1-0.5 μM) is sufficient to induce marked inhibition of constitutive and inducible Met phosphorylation and its resultant downstream signaling in MPNST cells, and inhibit HGF-induced MPNST cell migration and invasion. XL184 also induces marked inhibition of Met and VEGFR2 phosphorylation in cytokine-stimulated human umbilical vein endothelial cells (HUVECs). Although XL-184 has no significant effect on MPNST cell growth at 0.1 μM, XL184 at 5-10 μM significantly inhibits the MPNST cell growth. [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
E98NT MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M37kOVAvODFvMUCg{txOM{jreWROW09?M3v6RmlEPTB;OEmgcm0>MlXtNlM1QDRyME[=
SNU-5 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4jrfGlEPTB;IEG5JI5OMnf6NlE6OjZzOUG=
Hs746T M4fyPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYfJR|UxRTlwOTDuUS=>NEHvd2UzOTl{NkG5NS=>
SNU-1 M4XrSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mne4TWM2OD13MkKzJI5OM1;WN|IyQTJ4MUmx
H441 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXXaU5g1UUN3ME2yNVcxOCCwTR?=NIHudIIzOTl{NkG5NS=>

... Click to View More Cell Line Experimental Data

In vivo XL184 treatment at 30 mg/kg in RIP-Tag2 mice with spontaneous pancreatic islet tumors disrupts 83% of the tumor vasculature, reduces pericytes and empty basement membrane sleeves, causes widespread intratumoral hypoxia and extensive tumor cell apoptosis, and slows regrowth of the tumor vasculature after drug withdrawal, more significantly compared with XL999 that blocks VEGFR but not c-Met, leading to only 43% reduction in vascularity, suggesting that concurrent inhibition of VEGFR and other functionally relevant receptor tyrosine kinases (RTK) amplifies angiogenesis inhibition. XL184 also decreases invasiveness of primary tumors and reduces metastasis. [1] XL184 at 30 mg/kg/day significantly abrogates human MPNST xenografts growth and metastasis in SCID mice. [2] Administration of XL184 induces dose-dependent inhibition of tumor growth in breast, lung, and glioma tumor models, in association with decreased tumor and endothelial cell proliferation as well as increased apoptosis. A single oral dose of XL184 is sufficient to induce sustained tumor growth inhibition in MDA-MB-231 tumor-bearing mice and C6 tumor-bearing rats at 100 mg/kg and 10 mg/kg, respectively. [3]

Protocol(Only for Reference)

Cell Assay:


Cell lines ST88-14, STS26T, and MPNST724
Concentrations Dissolved in DMSO, final concentrations ~10 μM
Incubation Time 48 hours

Cells are exposed to various concentrations of XL184 for 48 hours. Cell growth is determined by MTS assays using CellTiter96 Aqueous Non-Radioactive Cell Proliferation Assay kit. Absorbance is measured at a wavelength of 490 nm, and the absorbance values of treated cells are presented as a percentage of the absorbance of untreated cells.

Animal Study:


Animal Models RIP-Tag2 transgenic mice in a C57BL/6 background with spontaneous pancreatic islet tumors
Formulation Suspended at a concentration of 5 mg/mL in sterile saline or water
Dosages ~60 mg/kg
Administration Oral gavage

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)
Body Surface Area (m2)0.0070.0250.
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)


[1] You WK, et al. Cancer Res, 2011, 71(14), 4758-4768.

[2] Torres KE, et al. Clin Cancer Res, 2011, 17(12), 3943-3955.

view more

Clinical Trial Information( data from, updated on 2015-11-14)

NCT Number Recruitment Conditions Sponsor
Start Date Phases
NCT02592356 Not yet recruiting Advanced Cancers|Endocrine Tumor M.D. Anderson Cancer Center January 2016 --
NCT02216578 Not yet recruiting Metastatic Gastrointestinal Stromal Tumor European Organisation for Research and Treatment of Cance  ...more European Organisation for Research and Treatment of Cancer - EORTC July 2015 Phase 2
NCT02496208 Recruiting Urothelial Cancer|Bladder Cancer|Genitourinary Cancer|Urogenital Neoplasms|Urogenital Cancer National Cancer Institute (NCI)|National Institutes of He  ...more National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) June 2015 Phase 1
NCT02315430 Recruiting Fallopian Tube Clear Cell Adenocarcinoma|Ovarian Clear Cell Adenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent  ...more Fallopian Tube Clear Cell Adenocarcinoma|Ovarian Clear Cell Adenocarcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma National Cancer Institute (NCI) April 2015 Phase 2
NCT02302833 Recruiting Neuroendocrine Tumors M.D. Anderson Cancer Center|Exelixis February 2015 --

view more

Chemical Information

Download Cabozantinib (XL184, BMS-907351) SDF
Molecular Weight (MW) 501.51


CAS No. 849217-68-1
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 100 mg/mL (199.39 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 30% propylene glycol, 5% Tween 80, 65% D5W 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

Customer Product Validation (4)

Click to enlarge
Source Cancer Discov 2014 4(7), 816-27. Cabozantinib (XL184, BMS-907351) purchased from Selleck
Method Western blot
Cell Lines A-375 melanoma cells
Concentrations 3 uM
Incubation Time
Results XL184 combined with PLX4720, compared to PLX 4720 alone, abrogated AXL-mediated induction of AKT phosphorylation and rescue of ERK phosphorylation but had no effect on AKT or ERK levels in A-375 cell lines.

Click to enlarge
Source Cell Death Dis 2014 5, e1471. Cabozantinib (XL184, BMS-907351) purchased from Selleck
Method MTT assay, Spheroid formation assay
Cell Lines GCTB stromal cells
Concentrations 10 uM
Incubation Time 7 days
Results Cabozantinib significantly reduced the cell number and viability, whereas methotrexate was minimally effective as evident from morphologic changes and the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. To investigate whether cabozantinib affects the self-renewal potential, spheroidal-growing cells were left untreated or were treated with cabozantinib and methotrexate, respectively. Seven days later, the spheroids were photographed, and their volumes were determined.

Click to enlarge
Source Liver Int 2014 10.1111/liv.12524. Cabozantinib (XL184, BMS-907351) purchased from Selleck
Method Fluorescence microscopy, flow cytometric analysis
Cell Lines HepG2/adr cells
Concentrations 0.75, 1.5, 5 uM
Incubation Time 3 h
Results As shown in A, the treatment of HepG2/adr cells with 1.5 uM cabozantinib significantly increased the intracellular accumulation of Dox and Rho123, as indicated by stronger red and green fluorescence intensity, respectively, compared with the corresponding negative controls. The fluorescence index of Dox was increased by 1.53- and 2.17-fold in HepG2/adr cells in the presence of 0.75 and 1.5 uM of cabozantinib respectively. The same doses of cabozantinib increased the fluorescence index of Rho123 2.16- and 3.43-fold in HepG2/adr cells.

Click to enlarge
Source Christina W Yde/CDM Danish Cancer Society Research Center Denmark. Cabozantinib (XL184, BMS-907351) purchased from Selleck
Method Cell growth assay
Cell Lines MCF-7 breast cancer cells
Concentrations 0-1.5 μM
Incubation Time 5 d
Results XL-184 potently inhibited the survival of MCF-7 cells in a dose-dependent manner.

Product Use Citation (13)

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related VEGFR Products

  • SU5402

    SU5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC50 of 20 nM, 30 nM, and 510 nM for VEGFR2, FGFR1, and PDGF-Rβ, respectively.

  • Erlotinib

    Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • R428 (BGB324)

    R428 (BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).

  • Regorafenib (BAY 73-4506)

    Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM in cell-free assays, respectively.

  • Axitinib

    Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.

    Features:Superior as second-line therapy relative to sorafenib (current standard-of-care).

  • Nintedanib (BIBF 1120)

    Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50 of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM in cell-free assays. Phase 3.

  • Lenvatinib (E7080)

    Lenvatinib (E7080) is a multi-target inhibitor, mostly for VEGFR2(KDR)/VEGFR3(Flt-4) with IC50 of 4 nM/5.2 nM, less potent against VEGFR1/Flt-1, ~10-fold more selective for VEGFR2/3 against FGFR1, PDGFRα/β in cell-free assays. Phase 3.

  • Vandetanib (ZD6474)

    Vandetanib (ZD6474) is a potent inhibitor of VEGFR2 with IC50 of 40 nM in a cell-free assay.

  • Pazopanib

    Pazopanib is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.

  • Pazopanib HCl (GW786034 HCl)

    Pazopanib HCl (GW786034 HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.

    Features:A multi-kinase inhibitor.

Recently Viewed Items

Tags: buy Cabozantinib (XL184, BMS-907351) | Cabozantinib (XL184, BMS-907351) ic50 | Cabozantinib (XL184, BMS-907351) price | Cabozantinib (XL184, BMS-907351) cost | Cabozantinib (XL184, BMS-907351) solubility dmso | Cabozantinib (XL184, BMS-907351) purchase | Cabozantinib (XL184, BMS-907351) manufacturer | Cabozantinib (XL184, BMS-907351) research buy | Cabozantinib (XL184, BMS-907351) order | Cabozantinib (XL184, BMS-907351) mouse | Cabozantinib (XL184, BMS-907351) chemical structure | Cabozantinib (XL184, BMS-907351) mw | Cabozantinib (XL184, BMS-907351) molecular weight | Cabozantinib (XL184, BMS-907351) datasheet | Cabozantinib (XL184, BMS-907351) supplier | Cabozantinib (XL184, BMS-907351) in vitro | Cabozantinib (XL184, BMS-907351) cell line | Cabozantinib (XL184, BMS-907351) concentration | Cabozantinib (XL184, BMS-907351) nmr
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us